STOCK TITAN

Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Shattuck Labs (NASDAQ: STTK) granted inducement stock options to two newly hired non-executive employees on November 10, 2026.

The awards cover 384,000 common shares at an exercise price of $4.85 per share, with a maximum term of 10 years. Each award vests 25% on the first anniversary of the employee’s start date, followed by equal monthly installments over 36 months. The independent Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4). Granted outside the 2020 Equity Incentive Plan, the options generally carry the same terms and conditions as awards under that plan.

Loading...
Loading translation...

Positive

  • None.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.384,000 stock options at a $4.85 exercise price create potential dilution if exercised.

Key Figures

Option shares: 384,000 shares Exercise price: $4.85 per share Maximum option term: 10 years +1 more
Option shares
384,000 shares
Aggregate inducement awards
Exercise price
$4.85 per share
Inducement stock options
Maximum option term
10 years
Stock options
Vesting schedule
25% on the first anniversary; remainder in equal monthly installments over 36 months
Each employee’s award

Key Terms

non-qualified stock options, exercise price, nasdaq listing rule 5635(c)(4)
3 terms
non-qualified stock options financial
"non-qualified stock options to purchase an aggregate of 384,000 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
exercise price financial
"with an exercise price of $4.85 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
nasdaq listing rule 5635(c)(4) regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

AUSTIN, Texas and DURHAM, N.C., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has granted inducement equity awards on November 10, 2026 (the “Grant Date”) to two newly-hired non-executive employees.

The inducement awards consist of non-qualified stock options to purchase an aggregate of 384,000 shares of Shattuck’s common stock with an exercise price of $4.85 per share. The stock options have a maximum term of 10 years. A total of 25% of each award will vest on the first anniversary of each employee’s start date, with the remainder vesting in equal monthly installments over the subsequent 36 months. The stock options were granted as a material inducement to the individuals’ employment and were approved by Shattuck’s independent Compensation Committee, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted outside of the Company’s 2020 Equity Incentive Plan, but are generally subject to the same terms and conditions that apply to awards granted under such plan.

About Shattuck Labs, Inc.

Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 blocking antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor & Media Contact:

Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the terms of Shattuck Labs’ November 2026 inducement option grants?

The grants cover 384,000 common shares at an exercise price of $4.85 per share for two newly hired non-executive employees. The options have a maximum term of 10 years. Each award vests 25% on the first anniversary of the employee’s start date, with the remainder vesting monthly over the subsequent 36 months.

Keep reading